Fer-in-Sol

Quick links to important sections

Fer-in-Sol

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fer-in-Sol

Property Description
Active Ingredient Ferrous Sulfate (a ferrous salt)
Form Oral solution, Liquid drops, or Syrup
Pharmacological Class Hematinic, Iron preparation, Mineral supplement
Common Use Replacing deficient iron stores in the body
Origin Synthetic agent

Definition and Pharmacological Class

Fer-in-Sol is a recognized brand name for an oral preparation classified as both a Hematinic and an Iron preparation. Its active ingredient is the chemical compound Ferrous Sulfate, a ferrous salt that provides a readily available source of elemental iron, an essential body mineral. This compound is the subject of extensive pharmacological studies supporting its therapeutic utility as a widely utilized agent for iron replacement. The preparation is clinically recognized for its role in enabling the synthesis of hemoglobin within red blood cells, a process critical for maintaining overall oxygenation.

As a Hematinic, the drug's fundamental purpose is to replace depleted iron stores, thereby supporting the body's capacity for oxygen transport and oxygen storage. Ferrous salts are recognized as core therapeutic agents for managing deficiencies.

Composition and Pharmaceutical Form

The Ferrous Sulfate compound in Fer-in-Sol is typically supplied as a liquid drops or oral solution, where the active ferrous salt is dissolved in an aqueous solution vehicle. This specific liquid formulation is a key differentiating factor, making it uniquely positioned for pediatric use, particularly for infants and children. The ability to administer the medicine as liquid drops ensures that the amount given can be easily measured and adjusted, distinguishing this single-ingredient product from fixed-dose solid forms.

Regulatory References

  1. Ferrous salt - eEML - Electronic Essential Medicines List

What side effects are possible with Fer-in-Sol?

Possible side effects and safety information

The safety profile for Fer-in-Sol, which contains the active ingredient Ferrous Sulfate, is structured around common gastrointestinal effects and critical safety warnings related to accidental ingestion.

Adverse Reaction Classifications

Official regulatory documents classify adverse reactions based on the frequency and the physiological system affected.

Classification Detail Examples (Regulatory Terminology)
Common Side Effects Nausea, vomiting, epigastric pain, diarrhea, constipation, and stomach discomfort.
System-Organ Class The primary domain for effects is Gastrointestinal Disorders. Reports of Immune System Disorders (hypersensitivity) and Dental/Oral System effects (tooth staining) are also documented.
Expected Physical Effect Darkening of stools is a consistent and expected physical effect of unabsorbed iron.

Serious Safety Considerations

The most significant safety note in all regulatory labeling concerns the risk of accidental ingestion. Accidental overdose of iron-containing products is the leading cause of fatal poisoning in children under six. Due to this risk, the product must be kept out of the reach and sight of young children.

Specific serious adverse reactions documented include ulceration of the esophagus or bronchus, which can occur if the oral preparation (e.g., tablets) is incorrectly swallowed or aspirated.

Safety-Related Restrictions

Ferrous sulfate preparations are strictly contraindicated (prohibited for use) in individuals with existing conditions that lead to iron overload, such as haemochromatosis or haemosiderosis. Furthermore, safety documents note that gastrointestinal discomfort may be more pronounced during the initial phase of treatment.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — official regulatory information for Fer-in-Sol

Overdose Scope

Documented overdose presentations: The clinical presentation of acute overdose is phased, starting with severe gastrointestinal injury that includes nausea, vomiting, abdominal pain, and potentially bloody or tarry stools. Systemic signs can progress to lethargy, hypotension, rapid pulse (tachycardia), metabolic acidosis, and seizures (convulsions).

Physiological systems affected (as stated in label): Gastrointestinal Tract, Cardiovascular System (shock, circulatory collapse), Central Nervous System, Hepatic System (necrosis, liver failure), and Renal System (anuria).

Dose-related or exposure-related factors (if applicable): Ingestion of elemental iron at doses greater than 60 mg/kg is associated with a high risk for severe systemic toxicity.

Population-specific overdose notes (if applicable): Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6, as stated in FDA labeling.

Emergency-response statements (as written in official documents): Seek emergency medical attention or call a doctor or poison control center immediately.

When immediate medical help is required (label-derived phrasing only): Acute iron overdosage is an acute emergency requiring urgent medical attention. Evaluation is required for ingestions of 40 mg/kg elemental iron or greater.

Overdose Classifications (high-level)

Severity classification (as defined in official documents): Fatal poisoning risk; associated with multi-organ failure and life-threatening shock.

Regulatory basis (EMA / FDA / etc.): FDA Prescribing Information and national health authority guidelines.

Overdose-context constraints (as defined in official documents): Treatment involves specialized procedures. The antidote, Deferoxamine (a chelating agent), is an adjunct to, and not a substitute for, standard supportive measures.

Resulting Overdose Structure

Official overdose statements:

  • Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6.
  • Acute iron overdosage is an acute emergency requiring urgent medical attention.
  • Overdose may present with nausea, vomiting, hypotension, and can progress to shock and organ failure.
  • Treatment requires hospital-level monitoring and the administration of the antidote Deferoxamine.

Connection to the overall overdose profile (2–4 sentences): Government regulatory documents define the overdose profile by strictly detailing the phasic systemic toxicity and the associated fatal risk, which mandates the urgent medical attention required for all suspected or confirmed cases. The profile emphasizes that immediate action is necessary because acute ingestion can rapidly lead to circulatory collapse and requires specialized, hospital-level management and antidote administration.

Therapeutic Uses of Fer-in-Sol

Quick Facts: Fer-in-Sol Therapeutic Domains

  • Supports addressing: Low blood levels of iron (iron deficiency).
  • Helps manage: Iron deficiency anemia (a condition resulting from insufficient iron).
  • Applicable for: Dietary supplementation of iron.

What Fer-in-Sol Treats: Main Uses and Benefits

Fer-in-Sol is an oral iron preparation that is utilized to address or support the prevention of low levels of iron in the body. The active compound, ferrous sulfate, provides a supplemental source of iron, an essential mineral that participates in the formation of red blood cells.

This preparation is indicated for the management of conditions related to iron inadequacy, primarily iron deficiency anemia. This type of anemia is characterized by a reduced number of red blood cells, which can be caused by insufficient iron intake from the diet, certain medical states, or specific physiological periods like pregnancy.

The routine use of an iron supplement like Fer-in-Sol assists the body in maintaining appropriate iron stores. Supplementation is typically recommended when dietary iron intake alone is determined to be insufficient to sustain normal physiological processes.

Regulatory References

  1. NIH MedlinePlus guidance on iron supplements

Eligibility and Restrictions for Use

Fer-in-Sol (Ferrous Sulfate) is subject to specific population eligibility rules defined by government regulatory agencies.

Category Eligibility Status
Contraindicated Populations Must not be used in patients with established Hemochromatosis or Hemosiderosis (iron overload disorders). Contraindication also applies to patients receiving repeated blood transfusions or those with Hemolytic Anemia unless co-existing iron deficiency is proven [Source 1.7, 2.4, 2.6].
Conditional Use / Restrictions Contraindicated in cases of active peptic ulceration or inflammatory bowel disease (e.g., ulcerative colitis). Caution is advised for those with a history of these conditions. Use is generally restricted during the first 12 weeks of pregnancy [Source 1.1, 1.7, 2.4].
Age-Related Rules Approved for use in adults and children. A major regulatory warning exists for children under six years of age because accidental overdose is a leading cause of fatal poisoning [Source 2.1, 2.4]. Use is not recommended in neonates (infants under four weeks old) [Source 1.7].
Pregnancy/Lactation Allowed after the first 12 weeks of pregnancy and allowed during lactation, with no known contraindications to breastfeeding [Source 2.1, 2.3].

Connection to the overall eligibility profile: Regulatory documents define who can and cannot use Fer-in-Sol by establishing formal contraindications that prohibit use in patients with iron accumulation disorders or active gastrointestinal disease. The profile further limits eligibility through specific restrictions for age groups and physiological states like early pregnancy, mandating conditional use or avoidance as defined in official government labeling.

What should I know about interactions with other medicines?

Fer-in-Sol Interactions with other medicines and products

The official regulatory profile for Ferrous Sulfate (Fer-in-Sol) is defined by pharmacokinetic absorption interference and specific prohibitions.

Contraindicated Combinations and Additive Risk

Co-administration with parenteral iron preparations is formally contraindicated due to the additive risk of systemic iron overload (hemochromatosis), which affects total iron stores.

Medications Requiring Timing Separation

Oral iron significantly reduces the absorption of numerous co-administered medicines through chelation, necessitating mandatory dose separation. Agents whose exposure is decreased include Levothyroxine, Quinolone antibiotics (e.g., Ciprofloxacin), Tetracycline antibiotics, Bisphosphonates, and certain antivirals like Dolutegravir. Conversely, the absorption of Ferrous Sulfate is decreased by substances such as antacids, Cholestyramine, and supplements containing calcium or zinc. To mitigate this interference, official labeling requires doses to be separated by periods ranging from one to six hours, depending on the specific interacting agent.

Food and Substance Constraints

The absorption of oral iron is impaired by specific dietary items. Regulatory documents advise against concurrent ingestion with milk, tea, coffee, eggs, and whole-grain cereals to ensure adequate iron bioavailability. These constraints are due to the formation of poorly soluble complexes that prevent systemic uptake.

Mechanism of Action

Mechanism of Action: Iron Supply and Pathway Integration

The mechanistic activity of Fer-in-Sol is the delivery of elemental ferrous iron ( Fe^2+), which is essential for several core physiological processes. Once absorbed, the iron is transported to precursor cells, primarily in the bone marrow, where it is incorporated into the protoporphyrin ring to synthesize heme. Heme is required for the formation of hemoglobin and myoglobin, thereby providing the necessary structural component for oxygen binding and transport within the red blood cells and muscle tissue, respectively.

Beyond oxygen transport, iron acts as a crucial cofactor in two other mechanistic domains: it is required by enzymes involved in DNA synthesis, which regulates erythropoiesis (red blood cell formation), and it is a necessary structural component of cytochrome enzymes in the mitochondria, which are fundamental to the cellular energy (ATP) generation pathway. Systemic delivery is facilitated by the carrier protein transferrin, and regulated storage occurs via the ferritin protein complex, maintaining the availability of the mineral.

Dosage and Administration Information

Fer-in-Sol is an oral preparation of ferrous sulfate, and its administration protocol is structured to ensure accurate dosing and proper intake.

The approved route of administration is oral only. Dosage, which ranges from once daily for prophylaxis to up to four times daily for active iron replacement therapy in adults, must be accurately measured using only the calibrated dropper or device provided with the product. Prophylactic dosing for infants, for instance, is typically 1 mL of the concentrated drops daily; all dosages for children under 12 years, however, require consultation with a healthcare professional.

For maximum absorption, the liquid is preferably administered between meals; however, it may be taken with food to mitigate any gastrointestinal discomfort. Prior to use, the bottle must be shaken well. While the solution or drops may be mixed with water or fruit juice, the product must not be mixed with milk or wine-based vehicles.

Treatment is typically long-term, continuing for several months (e.g., three to six months) to ensure that body iron stores are fully replenished after red blood cell indices have normalized. If a scheduled dose is missed, the general principle is to take the dose as soon as it is remembered, unless it is close to the time of the next dose, in which case the missed dose should be skipped.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Fer-in-Sol

The research base for oral ferrous sulfate primarily consists of studies that explore how oral iron preparations are used in contexts related to low iron levels and their prevention. The following overview describes the types of clinical evaluations conducted, the outcomes researchers monitored, and the areas where further data are being sought.

Evidence for Use in Iron Deficiency Anemia (IDA)

Research examining the use of ferrous sulfate for Iron Deficiency Anemia (IDA) is often structured around Randomized Controlled Trials (RCTs) and comprehensive systematic reviews. This research was evaluated in populations diagnosed with IDA, including adults, pregnant women, and young children.

In these studies, researchers monitored changes in key blood parameters. Primary measurements included changes in Hemoglobin (Hb) levels, a key oxygen-carrying protein, and Serum Ferritin levels, which reflect the body’s iron stores. Studies report how these iron markers evolved in the observed populations during the study period. These findings describe patterns observed in the studies and generally cover short- to intermediate-term follow-up durations, typically up to six months.

Evidence for Use in Iron Prophylaxis (Prevention)

Ferrous sulfate was studied for its use in preventing iron deficiency (prophylaxis) in populations considered to be at risk. This research explored scenarios involving the administration of oral iron preparations in specific settings, such as in infants and pregnant women.

Studies examined changes in basic biomarkers of iron status, primarily Serum Ferritin levels. Research also examined specific outcomes related to functional status in infants, such as measured scores for psychomotor development. Findings varied in consistency regarding non-hematologic outcomes across different studies. Research provides insight into short-term changes in biomarkers of iron status in these populations.

What Remains Uncertain About the Research

The available evidence landscape highlights key areas where certainty remains low or where research is ongoing. There is limited information for long-term outcomes regarding the effects of iron supplementation extending years beyond the treatment period. Specifically, the relationship between observed changes in iron status and long-term functional measures, such as development in children, is still being explored.

Furthermore, comparative evidence is lacking regarding the long-term patterns of administration and patient experience of different dosing schedules when applied broadly in clinical practice. The research describes patterns related to iron status changes, but certainty remains low regarding individualized prediction of response.

Key Studies & References

  1. Ferrous salt (WHO Essential Medicines List Entry)

Frequently Asked Questions (FAQ)

Common questions about Fer-in-Sol (FAQ)

Q: What is the difference between Fer-in-Sol and other iron pills?

Fer-in-Sol is a brand name for a product containing ferrous sulfate. Official drug sources note that other oral iron preparations may use different salts, such as ferrous fumarate or ferrous gluconate. These differences mean they may contain slightly different amounts of elemental iron and can lead to variations in the gastrointestinal side effects observed in some individuals.

Q: How long does it usually take to feel better after starting Fer-in-Sol?

Regulatory sources indicate that individuals with iron deficiency may observe changes in iron status biomarkers (e.g., ferritin) after several weeks. Symptom improvement is highly variable and often takes longer. Official guidance stresses that treatment typically continues for several months to ensure the body's overall iron stores are fully replenished.

Q: Can Fer-in-Sol be taken with vitamins or other supplements?

Ferrous sulfate is known to interact with certain minerals, such as calcium and zinc, which can significantly reduce the amount of iron the body absorbs. Conversely, official sources suggest that taking it with Vitamin C (ascorbic acid) may actually help increase iron absorption. The potential for reduced absorption often makes it necessary to separate the timing of the iron dose from other vitamins and supplements to manage interference.

Q: Is it true that taking Fer-in-Sol with citrus juice helps?

Regulatory instructions mention that the liquid ferrous sulfate can be mixed with fruit juice to help with administration. Taking iron with citrus juices, which often contain Vitamin C, is described in some official sources as potentially improving the body's ability to absorb the elemental iron.

Q: Can taking Fer-in-Sol cause diarrhea instead of constipation?

Yes, both constipation and diarrhea are listed among the common gastrointestinal side effects associated with ferrous sulfate preparations. These effects reflect how the body responds to unabsorbed iron in the digestive tract. These gastrointestinal effects are often most noticeable during the initial phase of treatment, as described in regulatory documents.

Q: Is the iron in Fer-in-Sol easy for the body to absorb?

Ferrous sulfate is generally considered to have a relatively high level of bioavailability (ease of absorption). However, its absorption can be easily impaired by certain common foods like milk, tea, and coffee, as well as some medications. The potential for external factors to impair absorption is why careful timing of the iron dose is often described as necessary in product information.

Q: Do children or infants need a prescription for Fer-in-Sol?

Ferrous sulfate products are often available for purchase without a prescription (over-the-counter) in various strengths and formulations. Due to the critical risk of accidental overdose in children, regulatory documentation mandates that iron supplementation for infants and children must be discussed with and supervised by a healthcare professional.

Q: Is Fer-in-Sol considered a dietary supplement or a medication?

Ferrous sulfate preparations are regulated as drugs when they are intended for the treatment of conditions like Iron Deficiency Anemia. Official documents classify the product as a Hematinic and an Iron preparation. Its core purpose, as recognized by health organizations, is the replacement of depleted iron stores.

Q: What are the main ingredients in Fer-in-Sol drops?

The sole active ingredient is Ferrous Sulfate. The liquid drops also contain various inactive ingredients, such as purified water, sweeteners, flavorings, and coloring agents. For patients with known sensitivities or allergies, the full list of inactive ingredients is available in the official product labeling.

Q: What should I know about drug interactions with Fer-in-Sol?

A key consideration is that oral iron can significantly reduce the absorption of other critical medicines, including certain antibiotics, levothyroxine (a thyroid medicine), and bisphosphonates. Conversely, antacids and supplements containing calcium or zinc can reduce the absorption of the iron itself. To manage potential drug interference and maximize iron absorption, regulatory documents define specific time separations required between the ferrous sulfate dose and doses of interacting medicines.

Q: Is Fer-in-Sol available in tablet or capsule form, or just liquid?

Ferrous sulfate is available under various brand names and as generics in a range of formats. These include the liquid oral solution and drops, as well as various forms of solid doses, such as standard tablets and extended-release tablets.

Q: Can people with kidney issues or liver issues use Fer-in-Sol?

Official information primarily cautions against use in patients with a history of liver problems or alcohol dependence due to the potential for iron accumulation. Caution is generally advised when iron supplementation is considered in the presence of kidney or liver conditions.

Q: Are there any warnings about Fer-in-Sol and accidental ingestion by pets?

The most significant regulatory warning addresses the risk of fatal poisoning from accidental ingestion by children under six. Official patient information also provides general advice to keep all medicines, including iron products, secured and out of the reach of children and pets.

Q: Are there different strengths or formulations of Fer-in-Sol?

Yes, ferrous sulfate products are available in different strengths and formulations to suit various treatment needs. These differences primarily relate to the concentration of the liquid or the total milligrams of elemental iron provided in each dose, such as in concentrated drops versus standard tablets.

Q: Are there any common allergies related to Fer-in-Sol?

Official drug documents note the possibility of hypersensitivity reactions, which are essentially allergic responses to the product. Signs of a serious allergic reaction may include developing a rash, swelling (especially of the face or tongue), or experiencing trouble breathing.

Q: How is the action of Fer-in-Sol described in scientific terms?

Ferrous sulfate works by supplying elemental iron (specifically, Fe^2+) to the body. This iron is essential for the creation of heme, which is a core component needed to synthesize hemoglobin. Hemoglobin is the protein in red blood cells that is responsible for carrying oxygen throughout the body.

Q: Is the coloring or taste additive in Fer-in-Sol a concern?

Ferrous sulfate liquid formulations contain inactive ingredients such as flavorings, sweeteners, and coloring agents. While these are generally approved for use, official documents note that the full list of inactive ingredients is available for patients with known allergies or sensitivities to review.

Q: Do health organizations issue guidance on Fer-in-Sol for general health?

The World Health Organization (WHO) includes ferrous salts on its essential medicines list, highlighting their importance as core therapeutic agents for deficiencies. Some official sources note that while important, iron products are not a substitute for a proper diet and their use for prevention is generally limited to populations considered at risk.

Q: What are the common side effects listed for Fer-in-Sol?

According to the official product information, the most common side effects are related to the gastrointestinal system. These typically include nausea, vomiting, stomach discomfort, constipation, and diarrhea. The darkening of stools is consistently noted as an expected and harmless physical effect of unabsorbed iron.

Q: Is Fer-in-Sol safe for older adults to use?

Most adults, including older adults, can use ferrous sulfate under the guidance of a healthcare professional. Regulatory resources do not place a specific age restriction on older adults. The professional guiding treatment determines the need for supplementation, as absorption capacity and dosing needs may vary in this population.

Q: Can Fer-in-Sol affect the results of a blood test?

Yes, regulatory and patient information notes that ferrous sulfate may interfere with the results of certain laboratory tests. Specifically, it can lead to false positive results for fecal occult blood tests (which check for blood in the stool). Official documentation states that lab personnel should be informed of the product's use.

Q: What kind of research supports the use of Fer-in-Sol?

The use of ferrous sulfate is supported by a body of research, including Randomized Controlled Trials (RCTs) and systematic reviews. These studies establish the product's role in the treatment of Iron Deficiency Anemia and its value in the prophylaxis (prevention) of low iron levels in at-risk groups.

Q: Are there any signs that Fer-in-Sol is not being absorbed properly?

A healthcare provider typically monitors iron absorption using follow-up blood tests that measure levels such as hemoglobin and ferritin. In cases where iron deficiency does not improve after a period of use, official sources suggest that potential issues such as inadequate absorption or ongoing blood loss are factors to be assessed.

How should Fer-in-Sol be stored and disposed of?

Storage and Disposal Requirements

Fer-in-Sol (ferrous sulfate oral solution) must be stored strictly according to regulatory labeling to maintain its stability and prevent accidental ingestion.


Official Storage Conditions

Requirement Specific Mandate
Temperature Store at controlled room temperature, typically 20 C to 25 C.
Protection Mandatory to protect from freezing and protect from light.
Container Preserve in a tight, light-resistant container with a child-resistant cap.
Child Safety Keep out of the reach of children due to the risk of fatal iron poisoning.

Disposal

Unused or expired ferrous sulfate should be disposed of in accordance with local regulations. The preferred method is using a community drug take-back program. If a program is unavailable, the medicine should be mixed with an undesirable substance, sealed in a bag, and placed in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fer-in-Sol found in:

A-Z Index: